Compare · ELV vs FLGT
ELV vs FLGT
Side-by-side comparison of Elevance Health Inc. (ELV) and Fulgent Genetics Inc. (FLGT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and FLGT operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.81B, about 174.6x FLGT ($520.0M).
- Over the past year, ELV is up 7.7% and FLGT is down 15.5% - ELV leads by 23.2 points.
- FLGT has been more active in the news (15 items in the past 4 weeks vs 3 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 9 for FLGT).
- Company
- Elevance Health Inc.
- Fulgent Genetics Inc.
- Price
- $419.85+0.37%
- $18.43+0.82%
- Market cap
- $90.81B
- $520.0M
- 1M return
- +11.18%
- +15.48%
- 1Y return
- +7.75%
- -15.50%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 3
- 15
- Recent ratings
- 23
- 9
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Fulgent Genetics Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)
Latest FLGT
- President and COO Xie Jian sold $38,382 worth of shares (2,146 units at $17.89), decreasing direct ownership by 0.58% to 367,605 units (SEC Form 4) (tax withholding)
- CFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.57% to 362,545 units (SEC Form 4) to cover taxes
- Chief Scientific Officer Gao Hanlin sold $30,191 worth of shares (1,688 units at $17.89), decreasing direct ownership by 0.17% to 990,374 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Hsieh Ming covered exercise/tax liability with 4,392 shares, decreasing direct ownership by 0.49% to 893,293 units (SEC Form 4) to satisfy withholding obligation
- Fulgent Presents Updated FID-007 Data at ASCO 2026
- President and COO Xie Jian sold $21,138 worth of shares (1,201 units at $17.60), decreasing direct ownership by 0.32% to 369,751 units (SEC Form 4) (for withholding tax)
- CFO and Treasurer Kim Paul covered exercise/tax liability with 1,168 shares, decreasing direct ownership by 0.32% to 364,632 units (SEC Form 4) (tax liability)
- Chief Scientific Officer Gao Hanlin sold $16,632 worth of shares (945 units at $17.60), decreasing direct ownership by 0.10% to 992,062 units (SEC Form 4) to cover withholding tax
- Amendment: SEC Form SCHEDULE 13D/A filed by Fulgent Genetics Inc.
- Chief Executive Officer Hsieh Ming covered exercise/tax liability with 2,949 shares, decreasing direct ownership by 0.33% to 897,685 units (SEC Form 4) (withholding tax)